<DOC>
	<DOCNO>NCT00725712</DOCNO>
	<brief_summary>This clinical study conduct multiple site determine best confirm response rate , safety , tolerability GSK1363089 treatment metastatic gastric carcinoma .</brief_summary>
	<brief_title>Study GSK1363089 Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<criteria>histologically confirm diagnosis advance metastatic gastric carcinoma , adenocarcinoma gastroesophageal junction distal esophagus . Subjects tumor gastroesophageal junction distal esophagus may eligible provided tumor squamous sarcomatous histology Measurable disease The subject consent provide paired tumor biopsy , directly prior commence study treatment Days 5 8 . The subject ECOG performance status ≤2 . The subject able ingest GSK1363089 capsule . In adrenocorticotropic hormone ( ACTH ) stimulation test , subject serum cortisol level ≥20 μg/dL ( 552 nmol/L ) 3090 minute injection ACTH . The subject liver , kidney marrow function . The subject capable understanding comply protocol sign informed consent document . Sexually active subject ( male female ) must use medicallyaccepted method contraception course study . Female subject childbearing potential must negative serum pregnancy test screening . The subject diagnosis malignancy ( unless nonmelanoma skin cancer malignancy diagnose ≥5 year ago , evidence disease 5 year prior screen study ) . QTc &lt; 470 msec . The subject receive two line prior cytotoxic chemotherapy locally advance metastatic disease . For purpose protocol , neoadjuvant therapy would consider prior cytotoxic chemotherapy . In addition , potential subject receive prior treatment cMET signal inhibitor exclude . The subject receive investigational drug within 14 day first dose study drug . The subject receive chemotherapy , immunotherapy , radiation therapy ( ≥25 % bone marrow ) within 14 day receive nitrosoureas mitomycin C within 6 week prior schedule first dose GSK1363089 . The subject AEs due investigational drug medication administer 21 day prior enrollment recover Grade ≤1 use NCI CTCAE v3.0 , exception alopecia great grade 1 . The subject know brain metastasis . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . The subject pregnant breastfeeding . The subject know positive human immunodeficiency virus ( HIV ) . The subject previously identify allergy hypersensitivity component GSK1363089 formulation . The subject unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>c-Met</keyword>
	<keyword>Metastatic Gastric Carcinoma</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>GSK1363089</keyword>
	<keyword>XL880</keyword>
	<keyword>MET inhibitor</keyword>
</DOC>